Purification of ovine placental lactogen (oPL) using high-performance liquid chromatography Evidence for two forms of oPL by Chan, John S.D. et al.
Volume 199, number 2 FEBS 35% April 1986 
Purification of ovine placental actogen (0PL) using 
high-performance liquid chromatography 
Evidence for tivo forms of oPL 
John S.D. Chan, Z.-R. Nie, N.G. Seidah and M. Chrttien 
Clinical Research Institute of Montreal (Afiliated to the University of Montreal), I10 Pine Avenue West, Montreal, 
Quebec H2 W 1 R7, Canada 
Received 25 February 1986 
After initial purification of ovine placental actogen (oPL) using the procedures described previously [( 1976) 
Endocrinology 98,65-751, the oPL preparation was further purified by high-performance liquid chromatog- 
raphy (HPLC) using an anionic exchange column (Bio-Sil TSK DEAE-ZSW). Two forms of oPL with dif- 
ferent relative mobilities on HPLC were isolated and designated oPL-I and oPL-II. Subsequent analysis 
by polyacrylamide gel electrophoresis containing SDS revealed that oPL-I and oPL-II are nearly homoge- 
neous (greater than 90% pure) and are identical in apparent M, (approx. 22 00&23 000). Like human growth 
hormone (hGH), oPL-I and oPL-II are equally active in the radioreceptor assays for growth hormone-like 
activity (RRA-GH) and for prolactin-like activity (RRA-RRL). In the radioimmunoassay of oPL, both 
oPL-I and oPL-II are immunologically similar. Analysis of amino acid composition revealed that oPL-I 
and oPL-II consist of 199 and 196 residues, respectively, and have almost identical residues except hat oPL- 
I has a higher content of glycine. Furthermore, both oPLs have a general similarity in amino acid composi- 
tion to oGH and oPRL except for a lower content of methionine and leucine but with a higher content 
of lysine. Our studies demonstrated the presence of two similar forms of oPL. Whether these two similar 
forms of oPL share identical primary structure remains to be determined. 
HPLC OvinepIacental lactogen 
1. INTRODUCTION 
Ovine placental actogen (oPL) is a polypeptide 
hormone which has been previously isolated [l-4]. 
It has been demonstrated that oPL has potent 
somatotropic and mammotropic activity in various 
bioassays [l-101. Furthermore, it has been shown 
that oPL inhibits glycogenolysis in fetal rat liver 
[l 11. We have also shown that oPL binds 
specifically to growth hormone receptor in ovine 
maternal and fetal tissues but not to lactogenic 
hormone receptors [12]. Thus, these studies sug- 
gested that oPL may play a physiological role in 
mammogenesis, in amino acid and protein 
metabolism during pregnancy. It may also play an 
important role in the maintenance of normal 
pregnancy and the support of fetal growth during 
gestation. On the other hand, little information is 
available on the chemistry of oPL. The only 
studies, performed by Hurley et al. [13], showed 
that oPL is similar to ovine growth hormone 
(oGH) and ovine prolactin (oPRL) in amino acid 
composition. The main obstacle to studies on the 
primary sequence of oPL is that it is very difficult 
to obtain a sufficient quantity of oPL pure enough 
for chemical characterization. This paper describes 
the use of high-performance liquid chromatog- 
raphy (HPLC) as a final procedure during the 
purification of oPL. By employing this method, 
one could obtain a nearly homogeneous oPL 
preparation. 
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2. MATERIALS AND METHODS 
2.1. Hormone preparations 
All hormone preparations listed below, with the 
exception of oPL, were kindly supplied by the 
NIAMDD of the National Institutes of Health 
(Bethesda, MD}: human growth hormone 
(NIADDK-hGH-I-l), ovine growth hormone 
(NIAMDD-oGH-12 and NIADDK-oGH-I-3), 
ovine prolactin (NIADDK-oPRL- 17 and 
NIAMDD-oPRL-I-I), and human placental lac- 
togen (hPL). 
2.2. ~ri~cat~~~ of 0PL 
oPL was prepared according to [I], with slight 
modifications. 2-4 mg oPL (> 1500-fold purifica- 
tion) were purified from 2-3 kg mid-term ovine 
placenta. The oPL preparation was further 
purified by HPLC using an anionic exchange col- 
umn (Bio-Sil TSK DEAE-2-SW, Bio-Rad). A 
linear gradient of O-25% of 0.5 M NaCl in 
0.025 M Tris-HCl, pH 8.0, over 200 min was 
employed. Fractions of 0.5 ml were collected and 
directly assayed for growth hormone-like activity 
using radioreceptor assay for GH (RRA-GH) [ 161. 
The fractions containing GH-like activity were ap- 
propriately pooled, desalted on a Sephadex G-15 
column and finally lyophilized. 
2.3. Characterization of oPL 
2.3.1. Polya~rylamide gel electrophoresis 
The purified oPL preparations were analyzed by 
polyacrylamide gel electrophoresis containing SDS 
using a linear gradient of lo-15% polyacryi~ide 
gel [ 14,151. The protein standard markers (low A4J 
were purchased from Pharmacia. 
2.3.2. Amino acid composition analysis 
After hydrolysis of oPL for 24, 48 and 72 h in 
6 N HCl at 110°C under reduced pressure, the 
amino acid composition was determined on a 
Beckman 121M microcolumn amino acid analyzer. 
The half-cystine content was determined as cysteic 
acid following oxidation with performic acid 1161; 
tryptophan was determined by the method of 
Edelhoch [17]. 
2.3.3. Radioreceptor assays 
The binding activities of the oPL preparations 
were examined in the radioreceptor assay for 
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growth hormone (RRA-GH) [ 181 and prolactin 
(RRA-PRL) 119). 
2.3.4. Radioimmunoassay (RIA) 
The double-antibody RIA procedure was similar 
to that which we described previously for oPL 
1201, with slight modifications using r2%iodinated 
oPL-I or ‘251-iodinated oPL-II as tracers. 
All iodinations were performed by a slight 
modification of the lactoperoxidase method of 
Thorell and Johansson [al]. 
3. RESULTS 
Fig.1 shows the elution profile of partially 
purified oPL preparations on HPLC using anionic 
exchange column. It is apparent that two major 
peaks of growth hormone-like (GH-like) activity 
corresponding to the two major protein peaks 
(monitored by absorbance at 280 nm) were ob- 
served. These two peaks of GH-like activity were 
designated oPL-I and oPL-II in ascending order. 
Analysis of the oPL prep~ations by 
polyacrylamide gel electrophoresis (lo- 15% gel) 
containing SDS, as shown in fig.2, revealed that 
the oPL preparation without the HPLC purifica- 
tion step (lanes B,C) is approx. 65-75% pure as 
shown by the staining intensity of the protein 
band. After further purification by HPLC, the 
0PL preparations (OPL-I, oPL-II) were nearly 
homogeneous as shown in lanes D and E. The ap- 
parent Mr values of oPL-I and oPL-II were 
calculated to be approx. 22000-23000, which are 
identical to that of the hPL standard. However, 
RETENllON TIME ,mnJ 
Fig. 1. HPLC of 0PL preparation using anionic 
exchange column (Bio-Sil TSK DEAE-2-SW, Bio-Rad). 
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Fig.2, Polyacrylamide gel electrophoresis (lo-15% 
gradient gel) containing SDS. Lanes: A,J, Pharmacia 
low-&& standard; B, oPL without purification on 
HPLC, 1Ogg; C, oPL without ~u~fi~tion on HPLC, 
2Ocg; 13, oPL-I, 10&g; E, oPL-II, 2Oyg; F, hGH 
NIADDK-hGH-I-l, 10 ,ug; G, hPL NIAMDD, 20 cg; H, 
oGH NIAMDD-oGH-12, 2Opg; I, oPRL NIADDK- 
OPRL-17, 2ocg. 
there was no apparent difference in A& between 
oPL-I and oPL-II on analysis by this method. 
The amino acid compositions af oPL-I and 
oPL-II are compared to those of aPL isolated by 
Hurley et al. [ 131, oCH, oPRL and hPL as shown 
in table 1, It is apparent hat oPL-I and oPL-II 
Table 1 
Amino acid composition of oPL, oGH, oPRL and hPLa 
Amino acid opt-1 oPL*ff oPLb oPRLc OGHd hPL’ 
Lys 14.6 (15) 16.3 (16) 14 9 13 9 
His 5.9 ( 6) 6.4 ( 6) 4 8 3 I 
Arg 9.7 (10) 9.7 (10) 10 11 13 11 
Asp lg.3 (18) 18.5 (19) 19 22 I6 22 
Thr 11.6 (12Zf 12.2 (12)f 10 9 f2 12 
Ser 16.9 (17)f 16.5 (17)f 15 15 12 18 
Glu 24 (24) 24 (24) 24 23 25 25 
Pro 9.9 (10) 9.6 (10) 10 11 8 5 
Gl Y 14.7 (15) 10.2 (10) 15 11 10 7 
Ala 12.2 (12) 11.7 (12) 13 9 14 6 
j/i-cystine 6.4 ( 6)9 N.D. 6 6 4 4 
Val 10.7 (11) 12.3 (12) 12 10 7 7 
Met 1s ( 2) 1.7 ( 2) 5 7 4 6 
lie 10.0 (10) 11.3 (11) 10 11 7 7 
Leu 17.1 (17) 15.8 (16) 13 22 22 25 
Tyr 5S ( 6) 6.2 ( 6) 4 7 6 8 
Phe 5.9 ( 6) 6.4 ( 6) 7 6 13 11 
Trp 2.4 f 2)& 2.3 ( 2)” 2 2 1 I 
Total 199 196 193 199 191 191 
Calculated Mr 22 103 21927 21418 22720 21806 21600 
a Values for amino acids are expressed as residues per molecule with nearest integral numbers in 
parentheses 
b 1131 From 
’ From f22] 
d From [23] 
’ From [24] 
’ Extrapolated to zero time of hydrolysis 
E Determined as cysteic acid after oxidation with performic acid (161 
’ Determined by the spectrophotometric method in fi7] 
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have almost identical residues except that oPL-I 
has a slightly higher content of glycine. Our oPL 
preparations are similar to that of Hurley et al. 
[ 131 except that our oPLs have a slightly higher 
content of leucine and tyrosine and a lower 
amount of methionine residue. Although our oPLs 
are not identical with oPRL in amino acid com- 
position, they are closer to oPRL than to oGH in 
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Fig.3. Radioreceptor assay for growth hormone-like 
activity (RRA-GH) using iodinated ovine growth 
hormone, oGH (NIADDK-oGH-I-3) and rabbit liver 
particulate fractions as tracer, standard and receptors, 
respectively (A). Radioreceptor assay for prolactin-like 
activity (RRA-PRL) using iodinated ovine prolactin, 
oPRL (NIAMDD-oPRL-I-1) and rabbit mammary 
gland particulate fractions as tracer, standard and 
receptors, respectively (B). 
content of histidine, arginine, proline, valine, 
isoleucine, phenylalanine and tryptophan. oPLs 
are closer to oGH in content of lysine, aspartic 
acid, threonine, methionine and tyrosine. In addi- 
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Fig.4. A double-antibody radioimmunoassay for oPL 
using iodinated oPL-I (A) and oPL-II (B) as tracer. 
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tion, our oPL preparations have almost no 
similarity to hPL except in content of histidine, 
arginine, threonine, serine and glutamic acid which 
are nearly the same. The estimated total number of 
residues in oPL-I and oPL-II are 199 and 196, 
respectively. The minimum h4, values of oPL-I and 
oPL-II, calculated from the amino acid composi- 
tion, are 22 103 and 21927, respectively. 
When the binding activities of oPL-I and oPL-II 
are analyzed in RRA-GH and RRA-PRL as shown 
in fig.3A and B, respectively, it is evident that 
oPL-I and oPL-II, like hGH, are both active in 
RRA-GH and in RRA-PRL. Furthermore, both 
oPL-I and oPL-II were equally active in both 
assays. 
Finally, oPL-I and oPL-II were tested in the 
RIA for oPL (antibodies raised in rabbits using 
oPL preparation without final purification by 
HPLC) using iodinated oPL-I and iodinated oPL- 
II as tracers as shown in fig.4A and B, respectively. 
These results showed that oPL-I and oPL-II were 
immunologically similar and equally potent in 
displacing the tracer. 
4. DISCUSSION 
By employing RRA-GH and/or RRA-PRL, 
various investigators have successfully isolated 
ovine placental lactogen from ovine placenta 
within the last 10 years [l-4]. To our knowledge, 
however, no investigator has reported the use of 
HPLC to purify oPL. Thus, this paper is the first 
report of the use of HPLC for purification of oPL. 
It is apparent hat HPLC gives superior separation 
to conventional ion-exchange chromatography 
(i.e. using ion-exchange cellulose). One of the 
disadvantages of using HPLC, however, is the 
relative low yield of the purified oPL. In our 
hands, we consistently had no more than lo-20% 
recovery in dry weight and in GH-like activity by 
using HPLC. Thus, we could only obtain approx. 
200-300 pg pure oPL from 2-3 kg ovine placenta 
(90-120 days gestation). On the other hand, we 
were very surprised that oPL was resolved into two 
forms, designated oPL-I and oPL-II. These two 
forms of oPL differ only in minor amino acid 
residues (table 1). These studies suggest hat oPL-I 
and oPL-II are probably also identical in primary 
amino acid sequence with only a minor amino acid 
substitution. Nevertheless, more studies on the 
chemical structure of oPL-I and oPL-II are 
definitely required to answer this question. 
It is interesting that both oPL-I and oPL-II were 
equally active in both RRA-GH and RRA-PRL 
(fig.3A,B). Furthermore, like hGH, both oPL-I 
and oPL-II were active in both RRAs, whereas 
oGH and oPRL were active in only one RRA. 
These studies suggest hat oPL is more similar to 
hGH structurally than to oGH and/or oPRL. At 
present, we do not know why the oPL-I and oPL- 
II preparations were only as active as the oPL 
preparation without purification by HPLC. One 
possible explanation might be that, during the final 
purification procedure using HPLC, some of the 
oPL might have been denatured. 
When tested in the RIA using iodinated oPL-I 
and oPL-II as tracers as shown in fig.4A and B, 
respectively, oPL-I and oPL-II were im- 
munologically the same. Thus, these studies fur- 
ther support the hypothesis that, like hPLs which 
are derived from two identical mRNAs [25,26], 
oPL-I and oPL-II might also be derived from two 
similar (if not identical) mRNAs. 
In conclusion, our studies demonstrate that oPL 
is purified to homogeneity and resolved into two 
forms by HPLC using an anionic exchange col- 
umn. These two forms of oPL are similar in ap- 
parent M,, amino acid composition and im- 
munological properties. Finally, our receptor- 
binding studies demonstrate that oPL-I and oPL- 
II are equally active in both RRA-GH and RRA- 
PRL, suggesting that these molecules could be 
derived from similar (if not identical) mRNAs. In- 
deed, further studies along these lines are definitely 
required. 
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